North America Immunoprecipitation Market

North America Immunoprecipitation Market Size (2023 to 2028)

By 2028, the market size for immunoprecipitation in the North American region is predicted to be worth USD 309.97 million from USD 235.36 million in 2023, growing at a CAGR of 5.66% from 2023 to 2028.

One of the key drivers encouraging the growth pace of the North American immunoprecipitation market is the increasing prospects for funding and investments in next-generation DNA sequencing and genomics research from both government and non-government groups.

Immunoprecipitation techniques have advanced significantly in terms of technology. For example, Chromatrap Immunoprecipitation (ChIP) technology, a bead-free method of chromatin immunoprecipitation, has been developed due to advances in chromatin immunoprecipitation technology. Because of epigenetic breakthroughs made possible by ChIP-seq, the market is expected to grow substantially in this region. Furthermore, the immunoprecipitation testing market is predicted to grow due to an increase in the frequency of autoimmune illnesses, which needs antibody-antigen interaction testing.

Due to increased research efforts in genetics, immunotherapy, and the microbiome, the breadth of new findings is growing. R&D for genomics for sickness research, medicine development, and personalized therapy design have developed significantly since improved genetic techniques. Furthermore, several regulatory and federal authorities are making concerted efforts to make genetic research more accessible.

The COVID-19 pandemic has dramatically boosted the usage of immunoprecipitation, which is crucial for examining protein-DNA interactions and target binding sequences for the novel coronavirus. As a result, the North American immunoprecipitation market is being propelled ahead by increased drug development research, a significant focus on COVID-19 vaccine development, and developments in ChIP applications in genomic investigations, as well as technological advancements in the ChIP process.

The advent of substitute technologies is predicted to hamper the growth of the North American immunoprecipitation market over the forecast period. The immunoprecipitation market, on the other hand, is likely to develop in the following years as a result of a stronger focus on biomarker identification. Concerns over the quality of research antibodies, on the other hand, could provide a significant impediment to the immunoprecipitation market's expansion in North America in the near future. Antibodies can become lodged in the pores of these sponge-like structures, making removal difficult. As a result, pre-clearing the cell lysate and lengthy washing is required when using agarose beads to reduce background.

This research report on the North American immunoprecipitation market has been segmented and sub-segmented into the following categories.

By Product:

• Kits

• Reagents

  • Antibodies

  • Beads

  • Others

By Type:

• Individual protein

• Protein complex

• Chromatin

• Ribonucleoprotein

• Tagged proteins

By End-User:

• Academic & Research Institutes

• Pharmaceutical & Biotechnology Companies

• Contract Research Organizations

By Country:

• The United States

• Canada

• Rest of North America

Due to the increased government subsidies and funding, particularly in biotechnology research, and growing awareness of personalized medicine. Growing collaborations and partnerships between businesses and colleges and a high concentration of major players in the region are projected to propel the studied industry in the region forward. Collaborations between researchers and organizations have assisted the expansion of the life science sector tremendously. Academic breakthroughs in cellular and genetic therapy have resulted in revolutionary biological therapeutic techniques. Because of a rise in COVID-19 instances, researchers use current technologies such as immunoprecipitation sequencing and genome analysis to examine DNA-protein interactions in the region, particularly in the United States.

Furthermore, companies in this field are creating improved chromatin immunoprecipitation procedures to increase their business.

Other government bodies, such as the National Human Genome Research Institute (NHGRI), have supported and funded research into the structure, function, and role of the human genome in human health and disease. In addition, according to a report released by the National Institutes of Health (NIH) in 2020, the prevalence of antinuclear antibodies (ANA), a sign of autoimmunity, has increased in the United States. As discussed above, several factors are expected to drive growth in the North American region during this projection period.

KEY MARKET PLAYERS:

Companies playing a significant role in the North American immunoprecipitation market profiled in this report are Merck KGaA, Thermo Fisher Scientific, Abcam, Bio-Rad Laboratories, Abbkine Scientific Co. Ltd., Cell Signaling Technology, Rockland Immunochemicals, BioLegend, Takara Bio, GenScript Biotech Corporation, and Geno Technology.